|Title:||Operational directive Ė management of community program for opiod pharmacotherapy (C-POP) patients in a hospital setting.|
|Document ID:||Operational Directive OD 0255/09|
|Date of issue:||Friday, 11 December 2009|
|Status:||NO LONGER APPLICABLE|
|Description:||Management of community program for opioid pharmacotherapy (C-POP) patients in a hospital setting. Update of OD 0028/07 due to amended poisons regulations|
|Legal requirements:||Please indicate if this Operational Directive is required to be issued under any specific legal instrument, eg. Health Act, etc.?
|Category:||Disaster Preparedness and Management|
|Period of effect:||from 12 November 2009 to 12 November 2014|
|Review date:||12 November 2014|
|Authorised by:||Dr Peter Flett, DIRECTOR GENERAL, DEPARTMENT OF HEALTH, 11-Dec-2009|
|Print version:||View print version|
Operational directive Ė management of community program for opiod pharmacotherapy (C-POP) patients in a hospital setting.
The Community Program for Opioid Pharmacotherapy (C-POP) in Western Australia provides pharmacotherapy treatment for opioid dependence through community based authorised opiate pharmacotherapy prescribers and public prescribers at Next Step Drug and Alcohol Services.
Opioid pharmacotherapies currently include methadone syrup and solution, buprenorphine sublingual tablets as Subutex® and buprenorphine with naloxone sublingual tablets as Suboxone®. They are supplied through authorised community pharmacies and at Next Step Drug and Alcohol Services to patients following assessment by an authorised C-POP prescriber.
When a patient receiving opioid pharmacotherapy is admitted to hospital, it is ESSENTIAL that the protocol attached is followed when continuation of therapy is required. Failure to follow the protocols will result in an increased risk for the patient from overdose.
Commencement in C-POP must be by an authorised C-POP prescriber and requires prior authorisation from the Chief Executive Officer of Health for each patient. Treatment may continue while in hospital provided it is safe to do so for up to one month. Consultation with the patient’s authorised C-POP prescriber should be sought if dose adjustment is considered necessary.
Enquiries concerning these protocols or for general information on the C-POP contact 9388 4980.
Dr Peter Flett
This circular last updated: Friday, 11 December 2009 at 10:15am